Trial results

$EIKN — EIK1001

Eikon Therapeutics, Inc. (EIKN) EIK1001: trial results in advanced melanoma, 2027.

Research by Catalyst Intel

The catalyst

"EIK1001: Prespecified interim analysis for advancement to Phase 3 for TeLuRide-006, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab in advanced melanoma, is anticipated in the first half of 2027"

— Eikon Therapeutics, 8-K filed 2026-11-12 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

EIKN-EIK1001-2026

Company

Eikon Therapeutics, Inc.

Kind

Trial results

Indication

advanced melanoma

Window

2027-01-01 – 2027-06-30

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.